<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714400</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD141272ARM5-1</org_study_id>
    <nct_id>NCT02714400</nct_id>
  </id_info>
  <brief_title>The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea</brief_title>
  <official_title>The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that obstructive sleep apnea (OSA) patients with a low
      arousal threshold may wake up too early during a respiratory event, before upper airway
      muscles can be activated to achieve stable ventilation. Thus, strategies to manipulate the
      respiratory arousal threshold could potentially improve the quality of sleep and sleep
      disordered breathing. Agents that raise arousal threshold are therefore likely to benefit
      some patients with OSA. The overall goal of this project is to determine the importance of
      the arousal threshold in OSA, determine which patients might benefit from a raised arousal
      threshold, and test this hypothesis by using pharmacological manipulation of the arousal
      threshold to achieve this goal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized double-blinded crossover pilot study. The investigators will test
      whether Venlafaxine has important effects on the apnea hypopnea index. Venlafaxine is a
      serotonin-norepinephrine reuptake inhibitor (SNRI) for the treatment of depression and
      anxiety. Venlafaxine increases serum serotonin level, which may affect arousal threshold.
      Furthermore, higher serotonin level theoretically may improve muscle tone, including upper
      airway muscle. Therefore, the investigators hypothesize that venlafaxine may decrease arousal
      threshold and improve muscle tone, leading to improvement of OSA.

      Eligible participants will undergo overnight polysomonography as described below and will
      receive either Venlafaxine(50 mg 2 hour prior to sleep) or placebo (in random order) followed
      roughly 7 days later with placebo or donepezil. This aim will allow us to test the impact of
      Venlafaxine on the apnea hypopnea index.

      The change in apnea hypopnea index will be compared in the Venlafaxine groups with the
      placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Apnea Hypopnea Index</measure>
    <time_frame>Baseline and 7-day follow up</time_frame>
    <description>The Apnea hypopnea index is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The change from baseline in apnea hypopnea index after a single dose of Venlafaxine will be evaluated using overnight polysomnography. An apnea hypopnea index less than five events per hour is considered within normal limits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nadir Oxygen Level During Sleep</measure>
    <time_frame>Baseline and 7-day follow up</time_frame>
    <description>Change from baseline in nadir oxygen level during sleep after a single dose of Venlafaxine will be evaluated using overnight polysomnography. A lower blood oxygen saturation during sleep is associated with a more severe obstructive sleep apnea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loop Gain</measure>
    <time_frame>Baseline and 7-day follow up</time_frame>
    <description>Loop gain 1 is used to describe the stability of ventilatory control. The change from baseline in loop gain after a single dose of Venlafaxine will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Threshold</measure>
    <time_frame>Baseline and 7-day follow up</time_frame>
    <description>Change from baseline in respiratory arousal threshold after single dose of Venlafaxine will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>Baseline and 7-day follow up</time_frame>
    <description>Change from baseline in sleep efficiency after single dose of Venlafaxine will be estimated using overnight polysomnography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Venlafaxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg of Venlafaxine before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One piece of placebo before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine 50mg before sleep</description>
    <arm_group_label>Venlafaxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One piece of placebo before sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-70 years

          -  sleep study (with apnea hypopnea index&gt;5)

          -  Diagnosis of obstructive sleep apnea

        Exclusion Criteria:

          -  Any known cardiac (apart from treated hypertension), pulmonary (including uncontrolled
             asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.

          -  Susceptible to stomach ulcers.

          -  co-administration of MAO inhibitors intended to treat psychiatric disorders
             (concurrently or within 14 days of discontinuing the MAO inhibitor); initiation of MAO
             inhibitor intended to treat psychiatric disorders within 7 days of discontinuing
             venlafaxine; initiation in patients receiving linezolid or intravenous methylene blue

          -  Pregnant women.

          -  History of hypersensitivity to Afrin, Lidocaine (all Aims) or venlafaxine

          -  History of bleeding diathesis and/or gastrointestinal bleeding.

          -  Glaucoma and Urinary Retention

          -  Use of any medications that may affect sleep or breathing.

          -  Use of any medications that have known interaction with venlafaxine and the
             interaction may significantly increase the risk of the subject or decrease the
             therapeutic effect of the medication.

          -  A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar
             disorder, major depression, panic or anxiety disorders.

          -  Substantial cigarette (&gt;5/day), alcohol (&gt;3oz/day) or use of illicit drugs.

          -  More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.

          -  Desaturations to below 70% lasting greater than 10 seconds in duration per event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013 Oct 15;188(8):996-1004. doi: 10.1164/rccm.201303-0448OC.</citation>
    <PMID>23721582</PMID>
  </reference>
  <reference>
    <citation>Carter SG, Berger MS, Carberry JC, Bilston LE, Butler JE, Tong BK, Martins RT, Fisher LP, McKenzie DK, Grunstein RR, Eckert DJ. Zopiclone Increases the Arousal Threshold without Impairing Genioglossus Activity in Obstructive Sleep Apnea. Sleep. 2016 Apr 1;39(4):757-66. doi: 10.5665/sleep.5622.</citation>
    <PMID>26715227</PMID>
  </reference>
  <reference>
    <citation>Deacon NL, Jen R, Li Y, Malhotra A. Treatment of Obstructive Sleep Apnea. Prospects for Personalized Combined Modality Therapy. Ann Am Thorac Soc. 2016 Jan;13(1):101-8. doi: 10.1513/AnnalsATS.201508-537FR. Review.</citation>
    <PMID>26569377</PMID>
  </reference>
  <reference>
    <citation>Edwards BA, Eckert DJ, McSharry DG, Sands SA, Desai A, Kehlmann G, Bakker JP, Genta PR, Owens RL, White DP, Wellman A, Malhotra A. Clinical predictors of the respiratory arousal threshold in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2014 Dec 1;190(11):1293-300. doi: 10.1164/rccm.201404-0718OC.</citation>
    <PMID>25321848</PMID>
  </reference>
  <reference>
    <citation>Eckert DJ, Younes MK. Arousal from sleep: implications for obstructive sleep apnea pathogenesis and treatment. J Appl Physiol (1985). 2014 Feb 1;116(3):302-13. doi: 10.1152/japplphysiol.00649.2013. Epub 2013 Aug 29. Review.</citation>
    <PMID>23990246</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>March 23, 2020</results_first_submitted>
  <results_first_submitted_qc>April 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2020</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Robert L. Owens</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>Arousal threshold</keyword>
  <keyword>Venlafaxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Venlafaxine First, Placebo Second</title>
          <description>50mg of Venlafaxine before sleep first night
1 Pill of Placebo before sleep second night</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Venlafaxine Second</title>
          <description>1 Pill of Placebo before sleep first night 50mg of Venlafaxine before sleep second night</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (&gt;4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age 35-64 years</population>
      <group_list>
        <group group_id="B1">
          <title>All Analyzed Participants</title>
          <description>All participants who were randomized, completed both study nights, and were included in the analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Apnea Hypopnea Index</title>
        <description>The Apnea hypopnea index is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The change from baseline in apnea hypopnea index after a single dose of Venlafaxine will be evaluated using overnight polysomnography. An apnea hypopnea index less than five events per hour is considered within normal limits.</description>
        <time_frame>Baseline and 7-day follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>The Apnea Hypopnea Index</title>
          <description>The Apnea hypopnea index is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The change from baseline in apnea hypopnea index after a single dose of Venlafaxine will be evaluated using overnight polysomnography. An apnea hypopnea index less than five events per hour is considered within normal limits.</description>
          <units>Events per Hour of Sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="16.5"/>
                    <measurement group_id="O2" value="46.1" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nadir Oxygen Level During Sleep</title>
        <description>Change from baseline in nadir oxygen level during sleep after a single dose of Venlafaxine will be evaluated using overnight polysomnography. A lower blood oxygen saturation during sleep is associated with a more severe obstructive sleep apnea.</description>
        <time_frame>Baseline and 7-day follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir Oxygen Level During Sleep</title>
          <description>Change from baseline in nadir oxygen level during sleep after a single dose of Venlafaxine will be evaluated using overnight polysomnography. A lower blood oxygen saturation during sleep is associated with a more severe obstructive sleep apnea.</description>
          <units>Percent Oxygen Saturation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="80.0" upper_limit="84.0"/>
                    <measurement group_id="O2" value="81.5" lower_limit="75.8" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Loop Gain</title>
        <description>Loop gain 1 is used to describe the stability of ventilatory control. The change from baseline in loop gain after a single dose of Venlafaxine will be estimated.</description>
        <time_frame>Baseline and 7-day follow up</time_frame>
        <population>In one subject loop gain could not be quantified.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Loop Gain</title>
          <description>Loop gain 1 is used to describe the stability of ventilatory control. The change from baseline in loop gain after a single dose of Venlafaxine will be estimated.</description>
          <population>In one subject loop gain could not be quantified.</population>
          <units>Dimensionless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.15"/>
                    <measurement group_id="O2" value="0.56" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arousal Threshold</title>
        <description>Change from baseline in respiratory arousal threshold after single dose of Venlafaxine will be estimated.</description>
        <time_frame>Baseline and 7-day follow up</time_frame>
        <population>In one subject arousal threshold could not be quantified.</population>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Threshold</title>
          <description>Change from baseline in respiratory arousal threshold after single dose of Venlafaxine will be estimated.</description>
          <population>In one subject arousal threshold could not be quantified.</population>
          <units>Percent V-eupnea</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.6" lower_limit="108.2" upper_limit="130.8"/>
                    <measurement group_id="O2" value="118.6" lower_limit="113.4" upper_limit="137.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency</title>
        <description>Change from baseline in sleep efficiency after single dose of Venlafaxine will be estimated using overnight polysomnography.</description>
        <time_frame>Baseline and 7-day follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine</title>
            <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Change from baseline in sleep efficiency after single dose of Venlafaxine will be estimated using overnight polysomnography.</description>
          <units>Percent Time in Bed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="16.7"/>
                    <measurement group_id="O2" value="72.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Venlafaxine</title>
          <description>50mg of Venlafaxine before sleep
Venlafaxine: Venlafaxine 50mg before sleep</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One piece of placebo before sleep
Placebo: One piece of placebo before sleep</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea without vomiting</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dillon Gilbertson</name_or_title>
      <organization>UCSD</organization>
      <phone>8582452155 ext 62155</phone>
      <email>dcgilbertson@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

